Judith Bushe

Mrs. Judith Bushe

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SRSylvia Rothenberger
Sylvia Rothenberger
DHDaniel L. Hurdiss
Daniel L. Hurdiss
MWMarcel Walser
Marcel Walser
FMFrancesca Malvezzi
Francesca Malvezzi
JMJennifer Mayor
Jennifer Mayor
JTJakob Trimpert
Jakob Trimpert
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we show that ensovibep, a trispecific DARPin (designed ankyrin repeat protein) clinical candidate, can engage the three units of the spike protein trimer of SARS-CoV-2 and inhibit ACE2 binding with high potency, as revealed by cryo-electron microscopy analysis. The cooperative binding together with the complementarity of the three DARPin modules enable ensovibep to inhibit frequent SARS-CoV-2 variants, including Omicron sublineages BA.1 and BA.2. In Roborovski dwarf hamsters infected with SARS-CoV-2, ensovibep reduced fatality similarly to a standard-of-care monoclonal antibody (mAb) cocktail. When used as a single agent in viral passaging experiments in vitro, ensovibep reduced the emergence of escape mutations in a similar fashion to the same mAb cocktail. These results support further clinical evaluation of ensovibep as a broad variant alternative to existing targeted therapies for Coronavirus Disease 2019 (COVID-19).

29 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CWChantal Viola Weißfuß
Chantal Viola Weißfuß
SWSandra-Maria Wienhold
Sandra-Maria Wienhold
MBMagdalena Bürkle
Magdalena Bürkle
BGBaptiste GABORIEAU
Baptiste GABORIEAU
JBJudith Bushe
Judith Bushe
GNGeraldine Nouailles
Geraldine Nouailles
Phage therapy of ventilator-associated pneumonia (VAP) is of great interest due to the rising incidence of multidrug-resistant bacterial pathogens. However, natural or therapy-induced immunity against therapeutic phages remains a potential concern. In this study, we investigated the innate and adaptive immune responses to two different phage cocktails targeting either Pseudomonas aeruginosa or Escherichia coli—two VAP-associated pathogens—in naïve mice without the confounding effects of a bacterial infection. Active or UV-inactivated phage cocktails or buffers were injected intraperitoneally daily for 7 days in C57BL/6J wild-type mice. Blood cell analysis, flow cytometry analysis, assessment of phage distribution and histopathological analysis of spleens were performed at 6 h, 10 days and 21 days after treatment start. Phages reached the lungs and although the phage cocktails were slightly immunogenic, phage injections were well tolerated without obvious adverse effects. No signs of activation of innate or adaptive immune cells were observed; however, both active phage cocktails elicited a minimal humoral response with secretion of phage-specific antibodies. Our findings show that even repetitive injections lead only to a minimal innate and adaptive immune response in naïve mice and suggest that systemic phage treatment is thus potentially suitable for treating bacterial lung infections.

15 March 2026 in Journal of Histochemistry & Cytochemistry
Verified
Journal Article
Open access
JBJudith Bushe
Judith Bushe
JFJenny Fürstenau
Jenny Fürstenau
FBFlorian Bartenschlager
Florian Bartenschlager
SDSimon Dökel
Simon Dökel
VJVladimir M. Jovanović
Vladimir M. Jovanović
AGAchim D. Gruber
Achim D. Gruber
The chloride channel regulator, calcium-activated-1, CLCA1, acts as a multifunctional secreted glycoprotein in anion channel modulation, mucus homeostasis, immune regulation, and other functions. So far, it has been described in goblet and other mucus-producing cells in mucous membranes, primarily of the respiratory, alimentary, and urogenital tracts. Here, we identify the expression of CLCA1 in fibroblast-like synoviocytes and superficial as well as, to a lesser extent, intermediate zone chondrocytes of diarthrodial articular joints. The expression pattern was found to be conserved in major joints in mice, pigs, and humans. First analyses of degenerate or infectious inflammatory joint conditions in mice or pigs, respectively, suggest rather continuous expression levels in articular disease. We speculate that CLCA1 may be involved in articular anion conductance, proteoglycan homeostasis, and inflammation of articular joints, possibly similar to analogous functions of this molecule as established in mucous membranes of the lungs and intestine:

11 May 2022 in Pneumologie
Verified
Journal Article
Closed access
MBM C Brack
M C Brack
MVM Vollgraf
M Vollgraf
GNGeraldine Nouailles
Geraldine Nouailles
IKI Korf
I Korf
SWS Wienecke
S Wienecke
MWMartin Witzenrath
Martin Witzenrath
Introduction Patients with chronic lung diseases, such as COPD, bronchiectasis or cystic fibrosis, frequently suffer from airway colonization with Pseudomonas aeruginosa. Recurrent exacerbations are associated with high morbidity and mortality. The management of these patients is complicated by increasing number of multi-drug resistant strains, creating a need for new therapeutic approaches. Bacteria-specific viruses (bacteriophages) have regained interest as therapeutic agents in recent years, although sufficient data on the use of bacteriophages produced according to good manufacturing practice (GMP) standards are mostly lacking. The aim of this preclinical study was to fill existing knowledge gaps by evaluating a GMP-manufactured phage cocktail against pulmonary infections with P. aeruginosa. Methods Ex vivo studies were performed on explanted human lung tissue infected with clinical P. aeruginosa isolates and treated with manufactured purified phages or control solution. At different time points, samples were collected for assessment of bacterial loads and phage titers. Mice were infected with P. aeruginosa or PBS and treated intratracheally 6h later with the phage cocktail or control solution. Subsequently, animals were analyzed regarding pathogen elimination, phage titers, inflammatory response, and histopathological alterations in the lungs. Results In explanted human lung tissue, phages reduced bacterial load in a dose-dependent manner. Phage titers remained stable and could be detected up to 24h after application. In mice, infection with P. aeruginosa induced histopathologically apparent pneumonia with infiltrating neutrophils. Intratracheal phage treatment reduced bacterial load 12h after infection, however, this effect declined at later time points. Histopathological examination revealed slightly reduced signs of inflammation in phage-treated animals. Active phages were evident locally and systemically at all time points analyzed at a constant level even in sham-infected and phage-treated mice. Analysis of blood cells showed no phage-specific response. Furthermore, no adverse effects were detected. Conclusion Our preclinical data support the deployment of a GMP-manufactured bacteriophage cocktail for clinical application. SMW and MW contributed equally Article published online: 11 May 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany